BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Viana SD, Reis F, Alves R. Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges. Oxid Med Cell Longev 2018;2018:3693625. [PMID: 30510618 DOI: 10.1155/2018/3693625] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Ali ES, Mitra K, Akter S, Ramproshad S, Mondal B, Khan IN, Islam MT, Sharifi-rad J, Calina D, Cho WC. Recent advances and limitations of mTOR inhibitors in the treatment of cancer. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02706-8] [Reference Citation Analysis]
2 Cheng X, Chen Q, Sun P. Natural phytochemicals that affect autophagy in the treatment of oral diseases and infections: A review. Front Pharmacol 2022;13:970596. [DOI: 10.3389/fphar.2022.970596] [Reference Citation Analysis]
3 Zhang Z, Sun Y, Xue J, Jin D, Li X, Zhao D, Lian F, Qi W, Tong X. The critical role of dysregulated autophagy in the progression of diabetic kidney disease. Front Pharmacol 2022;13:977410. [DOI: 10.3389/fphar.2022.977410] [Reference Citation Analysis]
4 Mohamed MA, Elkhateeb WA, Daba GM. Rapamycin golden jubilee and still the miraculous drug: a potent immunosuppressant, antitumor, rejuvenative agent, and potential contributor in COVID-19 treatment. Bioresour Bioprocess 2022;9:65. [PMID: 35730039 DOI: 10.1186/s40643-022-00554-y] [Reference Citation Analysis]
5 Oleksak P, Nepovimova E, Chrienova Z, Musilek K, Patocka J, Kuca K. Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015–2021). European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114498] [Reference Citation Analysis]
6 Hoff U, Markmann D, Thurn-Valassina D, Nieminen-Kelhä M, Erlangga Z, Schmitz J, Bräsen JH, Budde K, Melk A, Hegner B. The mTOR inhibitor Rapamycin protects from premature cellular senescence early after experimental kidney transplantation. PLoS One 2022;17:e0266319. [PMID: 35446876 DOI: 10.1371/journal.pone.0266319] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lee CH, Wan Y, Smith A, Xie R, Motzer RJ. Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma. Eur Urol Open Sci 2021;31:1-9. [PMID: 34467233 DOI: 10.1016/j.euros.2021.06.008] [Reference Citation Analysis]
8 Gilewski W, Banach J, Rogowicz D, Wołowiec Ł, Sielski S, Grześk G. Treatment of Hypertension Because of Immunosuppressive Therapy After Solid Organ Transplantation-Pharmacological Approach. J Cardiovasc Pharmacol 2021;77:735-44. [PMID: 34001720 DOI: 10.1097/FJC.0000000000001009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Guden DS, Temiz-Resitoglu M, Senol SP, Kibar D, Yilmaz SN, Tunctan B, Malik KU, Sahan-Firat S. mTOR inhibition as a possible pharmacological target in the management of systemic inflammatory response and associated neuroinflammation by lipopolysaccharide challenge in rats. Can J Physiol Pharmacol 2021;99:921-34. [PMID: 33641344 DOI: 10.1139/cjpp-2020-0487] [Reference Citation Analysis]
10 Brooks DL, Garza AE, Caliskan Guzelce E, Gholami SK, Treesaranuwattana T, Maris S, Ranjit S, Tay CS, Lee JM, Romero JR, Adler GK, Pojoga LH, Williams GH. mTORC1 Deficiency Modifies Volume Homeostatic Responses to Dietary Sodium in a Sex-Specific Manner. Endocrinology 2020;161:bqaa041. [PMID: 32154868 DOI: 10.1210/endocr/bqaa041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Chow RY, Levee TM, Kaur G, Cedeno DP, Doan LT, Atwood SX. MTOR promotes basal cell carcinoma growth through atypical PKC. Exp Dermatol 2021;30:358-66. [PMID: 33617094 DOI: 10.1111/exd.14255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
12 Zulkipli NN, Zakaria R, Long I, Abdullah SF, Muhammad EF, Wahab HA, Sasongko TH. In Silico Analyses and Cytotoxicity Study of Asiaticoside and Asiatic Acid from Malaysian Plant as Potential mTOR Inhibitors. Molecules 2020;25:E3991. [PMID: 32887218 DOI: 10.3390/molecules25173991] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
13 Abdullah A, Mohd Murshid N, Makpol S. Antioxidant Modulation of mTOR and Sirtuin Pathways in Age-Related Neurodegenerative Diseases. Mol Neurobiol 2020;57:5193-207. [PMID: 32865663 DOI: 10.1007/s12035-020-02083-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
14 Nair N, Chakraborty R, Mahajan Z, Sharma A, Sethi SK, Raina R. Renal Manifestations of Tuberous Sclerosis Complex. J Kidney Cancer VHL 2020;7:5-19. [PMID: 32953421 DOI: 10.15586/jkcvhl.2020.131] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Lund-Ricard Y, Cormier P, Morales J, Boutet A. mTOR Signaling at the Crossroad between Metazoan Regeneration and Human Diseases. Int J Mol Sci 2020;21:E2718. [PMID: 32295297 DOI: 10.3390/ijms21082718] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
16 Goligorsky MS. Chronic Kidney Disease: A Vicarious Relation to Premature Cell Senescence. Am J Pathol 2020;190:1164-71. [PMID: 32194054 DOI: 10.1016/j.ajpath.2020.01.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
17 Li G, Kidd J, Li PL. Podocyte Lysosome Dysfunction in Chronic Glomerular Diseases. Int J Mol Sci 2020;21:E1559. [PMID: 32106480 DOI: 10.3390/ijms21051559] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
18 Ganesan H, Balasubramanian V, Iyer M, Venugopal A, Subramaniam MD, Cho SG, Vellingiri B. mTOR signalling pathway - A root cause for idiopathic autism? BMB Rep 2019;52:424-33. [PMID: 31186084 [PMID: 31186084 DOI: 10.5483/bmbrep.2019.52.7.137] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
19 Bhaoighill MN, Dunlop EA. Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics. Cancer Drug Resist 2019;2:1069-85. [PMID: 35582282 DOI: 10.20517/cdr.2019.87] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Uil M, Hau CM, Ahdi M, Mills JD, Kers J, Saleem MA, Florquin S, Gerdes VEA, Nieuwland R, Roelofs JJTH. Cellular origin and microRNA profiles of circulating extracellular vesicles in different stages of diabetic nephropathy. Clin Kidney J 2021;14:358-65. [PMID: 33564439 DOI: 10.1093/ckj/sfz145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
21 Li X, Luo F, Li J, Luo C. MiR-183 delivery attenuates murine lupus nephritis-related injuries via targeting mTOR. Scand J Immunol 2019;90:e12810. [PMID: 31325389 DOI: 10.1111/sji.12810] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
22 Huang D, Shen S, Cai M, Jin L, Lu J, Xu K, Zhang J, Feng G, Hu Y, Zheng K, Feng X. Role of mTOR complex in IGF-1 induced neural differentiation of DPSCs. J Mol Histol 2019;50:273-83. [PMID: 31049797 DOI: 10.1007/s10735-019-09825-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]